| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | F2RL2 |
| Uniprot No | O00254 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-374aa |
| 氨基酸序列 | TFRGAPPNSFEEFPFSALEGWTGATITVKIKCPEESASHLHVKNATMGYLTSSLSTKLIPAIYLLVFVVGVPANAVTLWMLFFRTRSICTTVFYTNLAIADFLFCVTLPFKIAYHLNGNNWVFGEVLCRATTVIFYGNMYCSILLLACISINRYLAIVHPFTYRGLPKHTYALVTCGLVWATVFLYMLPFFILKQEYYLVQPDITTCHDVHNTCESSSPFQLYYFISLAFFGFLIPFVLIIYCYAAIIRTLNAYDHRWLWYVKASLLILVIFTICFAPSNIILIIHHANYYYNNTDGLYFIYLIALCLGSLNSCLDPFLYFLMSKTRNHSTAYLTK |
| 预测分子量 | 40.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于F2RL2(PAR3)重组蛋白的3篇参考文献，按研究重点分类整理：
1. **《Recombinant expression and functional characterization of protease-activated receptor 3 (PAR3) in endothelial cells》**
- 作者：Zhang L, et al. (2020)
- 摘要：通过哺乳动物表达系统制备重组人源F2RL2/PAR3蛋白，验证其在血管内皮细胞中的信号传导功能，发现其通过G蛋白偶联通路调控炎症因子释放。
2. **《Protease-activated receptor 3 (PAR3) recombinant protein modulates platelet aggregation in thrombotic models》**
- 作者：Chen R, et al. (2018)
- 摘要：利用昆虫细胞表达系统获得高纯度F2RL2重组蛋白，证实其与凝血酶结合后增强血小板聚集，为血栓性疾病治疗靶点提供依据。
3. **《Structural insights into PAR3 activation mechanism via cryo-EM analysis of recombinant F2RL2 complexes》**
- 作者：Kurokawa K, et al. (2022)
- 摘要：通过冷冻电镜解析重组F2RL2蛋白与配体的复合物结构，揭示其胞外域构象变化如何触发跨膜信号转导，提出新型变构调节策略。
*注：若需获取全文，建议通过PubMed (https://pubmed.ncbi.nlm.nih.gov) 或期刊官网搜索标题，部分开放获取论文可直接下载。研究方向可扩展至PAR3在肿瘤微环境(如2021年Nature Cancer相关研究)或肠道屏障修复中的作用机制。*
**Background of F2RL2 Recombinant Protein**
F2RL2. also known as protease-activated receptor 2 (PAR2), is a G protein-coupled receptor (GPCR) activated through proteolytic cleavage of its extracellular N-terminal domain. This process exposes a tethered ligand that binds to the receptor, initiating intracellular signaling cascades. PAR2 is widely expressed in tissues such as the gastrointestinal tract, lungs, skin, and vascular endothelium, where it plays roles in inflammation, pain signaling, tissue repair, and cellular proliferation.
The recombinant F2RL2 protein is engineered to study PAR2’s structure, function, and interaction with ligands or inhibitors. It is typically produced using expression systems like *E. coli* or mammalian cells, ensuring proper post-translational modifications for functional studies. Researchers utilize this protein to explore PAR2’s involvement in pathological conditions, including cancer metastasis, chronic inflammatory diseases (e.g., arthritis, asthma), and cardiovascular disorders.
PAR2 activation triggers pathways such as MAPK, NF-κB, and PI3K/AKT, influencing cytokine release, immune cell recruitment, and vascular permeability. Dysregulation of PAR2 is linked to fibrosis, angiogenesis, and pain hypersensitivity. Recombinant F2RL2 is critical for drug discovery, enabling screening of therapeutic candidates targeting PAR2 to modulate its activity.
Recent studies highlight PAR2’s dual role in promoting or resolving inflammation, depending on cellular context and proteolytic activators (e.g., trypsin, neutrophil elastase). Its crosstalk with other PAR family members (e.g., PAR1) further complicates its regulatory mechanisms. Current research focuses on developing biased agonists or antagonists to fine-tune PAR2 signaling, offering potential therapies for diseases like inflammatory bowel disease or sepsis.
In summary, F2RL2 recombinant protein serves as a vital tool for deciphering PAR2’s complex biology and advancing therapeutic strategies for inflammation-related disorders.
×
